Videos

Sharyn Katz, MD, MTR, provides an overview on the potential for diagnostic ambiguity in the radiology of Covid-19, a topic she presented at the 2022 GDU Lung Cancers virtual meeting.

Thomas Martin, MD, discusses an updated analysis of the CARTITUDE-1 trial, in which ciltacabtagene autoleucel maintained deep and durable responses in heavily pretreated patients with MM at a follow-up of 28 months.

Corey Langer, MD, provides an overview on the potential of immune checkpoint inhibitors for the treatment of malignant pleural mesothelioma, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.

Corey Langer, MD, provides an overview on the potential for immune checkpoint inhibitors in the treatment of thymic malignancies, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.

Pasi Jänne, MD, shares insights about the recent FDA approval of trastuzumab deruxtecan for patients with HER2-mutant non-small cell lung cancer and the data that led to this approval.

Corey Langer, MD, provides an overview on the potential of tumor treatment fields for the treatment of advanced NSCLC, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.

David Tougeron, MD, reviews results from the PRODIGE 59-DURIGAST trial evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab as a second-line treatment for patients with advanced gastric or GEJ cancer.

Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.

Matthew Goetz, MD, highlights findings from the ELAINE 1 trial exploring lasofoxifene vs fulvestrant for patients with ESR1-mutated locally advanced or metastatic breast cancer who progressed on aromatase and CDK4/6 inhibitors.

Keiichi Fujiwara, MD, PhD, discusses findings from a phase 3 trial that evaluated maintenance chemotherapy with tegafur-uracil compared to observation following concurrent chemoradiotherapy in patients with locally advanced cervical cancer.